Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 15/20 | 0.44 |
| ▸ | FNTB | P49356 | 15/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 9/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3571119 | 0.99 | CYP11B2 (0.56) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3576163 | 0.90 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3466043 | 0.86 | CYP11B2 (0.65) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3466041 | 0.86 | CYP11B2 (0.65) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3568461 | 0.85 | CYP11B2 (0.61) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3465432 | 0.77 | CYP11B2 (0.55) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3465435 | 0.77 | CYP11B2 (0.55) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3579058 | 0.76 | CYP11B2 (0.52) | CYP11B2CYP11B1 | |
| SCHEMBL3464840 | 0.76 | CYP11B2 (0.62) | CYP11B2CYP11B1CYP19A1FNTAFNTB | |
| SCHEMBL3464837 | 0.76 | CYP11B2 (0.62) | CYP11B2CYP11B1CYP19A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | claimed |
| EP-1537114-B8 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2007-10-03 | — | — | EP | claimed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | claimed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | claimed |
| EP-1537114-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | Novartis AG (CH) | 2005-06-08 | — | — | EP | claimed |
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | claimed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7732603-B2 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2010-06-08 | — | — | US | disclosed |
| EP-1537114-B8 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1537114-B1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| EP-1537114-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004014914-A1 | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF ALDOSTERONE MEDIATED CONDITIONS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166973-A1 | Organic compounds as agents for the treatment of aldosterone mediated conditions | CYP11B1, CYP27A1, CYP17A1 | CYP11B2 6/4885CYP11B1 1/4885CYP19A1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.